A Search Service for Abbreviation / Long Form

■ Search Result - Abbreviation : PD-1

Search Conditions:
Search Keyword : PD-1
Search Method : Exact match.
Research Area:

Results:  
Abbreviation: PD-1
Appearance Frequency: 3747 time(s)
Long forms: 39

Display Settings:
[Entries Per Page]
 per page
Page Control
Page: of
Long Form No. Long Form Research Area Co-occurring Abbreviation PubMed/MEDLINE Info. (Year, Title)
programmed death-1
(3339 times)
Neoplasms
(1044 times)
PD-L1 (1007 times)
CTLA-4 (398 times)
NSCLC (311 times)
0 [Advances in Immunotherapy of Malignant Melanoma].
anti-programmed cell death-1
(304 times)
Neoplasms
(154 times)
PD-L1 (90 times)
NSCLC (57 times)
CTLA-4 (38 times)
2008 Circulating CD4+ CD25+ regulatory T cells correlate with chronic hepatitis B infection.
programmed death protein-1
(54 times)
Neoplasms
(17 times)
PD-L1 (19 times)
NSCLC (7 times)
CTLA-4 (5 times)
2014 Ninety-day survival rate of patients with sepsis relates to programmed cell death 1 genetic polymorphism rs11568821.
programmed cell death-1 molecule
(5 times)
Medicine
(1 time)
CTLA-4 (2 times)
aGVHD (1 time)
CMV (1 time)
2009 Increased programmed death-1 molecule expression in cytomegalovirus disease and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation.
Anti-Programed Death 1
(3 times)
Neoplasms
(2 times)
AFP (1 time)
aNSCLC (1 time)
BMI (1 time)
2016 Clinical Response of a Patient to Anti-PD-1 Immunotherapy and the Immune Landscape of Testicular Germ Cell Tumors.
PD-L1 and programmed cell death
(3 times)
Neoplasms
(2 times)
PD-L1 (2 times)
ADC (1 time)
APACHE (1 time)
2018 PD-L1 Overexpression During Endotoxin Tolerance Impairs the Adaptive Immune Response in Septic Patients via HIF1alpha.
anti-PDCD1
(2 times)
Neoplasms
(1 time)
B2M (1 time)
FSP (1 time)
MMR (1 time)
2018 High numbers of PDCD1 (PD-1)-positive T cells and B2M mutations in microsatellite-unstable colorectal cancer.
anti-programmed cell death-1 protein receptor
(2 times)
Neoplasms
(2 times)
CI (1 time)
ctDNA (1 time)
ctDNA TMB (1 time)
2016 Biomarkers for PD-1/PD-L1 Blockade Therapy inNon-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?
PDCD1, CD279
(2 times)
Pathology
(1 time)
ALDH1 (1 time)
AML (1 time)
2018 Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesothelioma.
10  programmed death 1 positive
(2 times)
Medicine
(1 time)
ICOS (2 times)
AUC (1 time)
BCL6 (1 time)
2016 [Detection of peripheral follicular helper T cells in rheumatoid arthritis].
11  Programmed death cell 1
(2 times)
Neoplasms
(1 time)
T1D (3 times)
CD (1 time)
PBMC (1 time)
2016 PD-1 Axis Inhibitors in EGFR- and ALK-Driven Lung Cancer: Lost Cause?
12  protein death-1
(2 times)
Immune System Diseases
(1 time)
CTLA-4 (1 time)
ICB (1 time)
2016 PD1-Expressing T Cell Subsets Modify the Rejection Risk in Renal Transplant Patients.
13  Anti(alpha)-programmed cell death-1
(1 time)
Immunotherapy
(1 time)
DLN (1 time)
IL (1 time)
M-MDSC (1 time)
2020 Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist.
14  anti-PD-1 was used to activate or block the programmed death
(1 time)
Medicine
(1 time)
CD28 (1 time)
ELISA (1 time)
IFN-gamma (1 time)
2019 PD-1/PD-L1 pathway activation restores the imbalance of Th1/Th2 and treg/Th17 cells subtypes in immune thrombocytopenic purpura patients.
15  anti-PD-L1/anti- programmed cell death 1
(1 time)
Neoplasms
(1 time)
DFS (1 time)
LNMs (1 time)
PD-L1 (1 time)
2018 Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer.
16  antiprogrammed death 1
(1 time)
Neoplasms
(1 time)
PD-L1 (1 time)
2019 A Histologically Complete Response to Immunotherapy Using Pembrolizumab in a Patient with Giant Cell Carcinoma of the Lung: An Additional Report and Literature Review.
17  CAMPANELLIProgrammed Death 1
(1 time)
Dental Pulp Diseases
(1 time)
PD-L1 (2 times)
2019 CAMPANELLIProgrammed Death 1 (PD-1) and PD-1 Ligand (PD-L1) Expression in Chronic Apical Periodontitis.
18  death protein 1 receptor
(1 time)
cSCC (1 time)
2020 Complete Resolution of a Large, Locally-advanced Cutaneous Squamous Cell Carcinoma with the Immune-modulating PD-1 Inhibitor Pembrolizumab.
19  death-protein 1
(1 time)
Drug Therapy
(1 time)
Ab (1 time)
CTL (1 time)
DCs (1 time)
2019 A Toll-like receptor 3 (TLR3) agonist ARNAX for therapeutic immunotherapy.
20  particularly antiprogrammed death 1
(1 time)
Neoplasms
(1 time)
CPI (1 time)
2019 Immunotherapy in recurrent and or metastatic squamous cell carcinoma of the head and neck.
21  PD-1 decoy
(1 time)
Immunity
(1 time)
PD-L1 (1 time)
2016 Enhanced Anti-tumor Reactivity of Cytotoxic T Lymphocytes Expressing PD-1 Decoy.
22  PD-1 expressed on T cells and its ligands
(1 time)
Neoplasms
(1 time)
MDSC (1 time)
TAM (1 time)
TIL (1 time)
2013 Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer.
23  PD-1 expression
(1 time)
Acquired Immunodeficiency Syndrome
(1 time)
ART (1 time)
2020 T cells with high PD-1 expression are associated with lower HIV-specific immune responses despite long-term antiretroviral therapy.
24  PD-1.1, PD-1.3, PD-1.5, PD-1.9
(1 time)
Clinical Medicine
(1 time)
CI (1 time)
CTLA-4 (1 time)
NSCLC (1 time)
2015 Polymorphisms of co-inhibitory molecules (CTLA-4/PD-1/PD-L1) and the risk of non-small cell lung cancer in a Chinese population.
25  PD-1ECD
(1 time)
Natural Science Disciplines
(1 time)
--- 2016 High-resolution crystal structure of the therapeutic antibody pembrolizumab bound to the human PD-1.
26  PD-1ex
(1 time)
Hematology
(1 time)
AML (1 time)
BiTE (1 time)
CiTE (1 time)
2018 Bifunctional PD-1 alphaCD3 alphaCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia.
27  PD-1hi
(1 time)
Allergy and Immunology
(1 time)
IO (1 time)
MIBC (1 time)
TME (1 time)
2018 Urine-derived lymphocytes as a non-invasive measure of the bladder tumor immune microenvironment.
28  PD-L1 and its receptor
(1 time)
Hematology
(1 time)
PD-L1 (1 time)
2017 Clinical applications of PD-L1 bioassays for cancer immunotherapy.
29  PD-L1 mRNA levels were independent poor prognostic factors for OS
(1 time)
General Surgery
(1 time)
GC (1 time)
OS (1 time)
PB (1 time)
2018 Prognostic Impact of Immune-Related Gene Expression in Preoperative Peripheral Blood from Gastric Cancer Patients.
30  PDCD-1
(1 time)
Molecular Biology
(1 time)
ACT (1 time)
TIL (1 time)
ZFNs (1 time)
2015 Clinical Scale Zinc Finger Nuclease-mediated Gene Editing of PD-1 in Tumor Infiltrating Lymphocytes for the Treatment of Metastatic Melanoma.
31  Pembrolizumab: a novel antiprogrammed death 1
(1 time)
Pharmacy
(1 time)
--- 2015 Pembrolizumab: a novel antiprogrammed death 1 (PD-1) monoclonal antibody for treatment of metastatic melanoma.
32  percentages of GC TFH (CXCR5(high)PD-1(high)) and CXCR5(+)programmed cell death-1
(1 time)
Allergy and Immunology
(1 time)
EF (1 time)
GC (1 time)
TFH (1 time)
2016 Germinal Center T Follicular Helper Cells Are Highly Permissive to HIV-1 and Alter Their Phenotype during Virus Replication.
33  pPD-1A
(1 time)
Biotechnology
(1 time)
GFP (1 time)
2004 [Eukaryotic expression and functional characterization of PD-1 extracellular domain].
34  Priya Darshini-1
(1 time)
Nutritional Sciences
(1 time)
PR (1 time)
1986 Genetic regulation of carotene biosynthesis in selected tomato strains: aspects of beta-carotene biosynthesis and B gene specificity.
35  programmed death 1 coinhibitory receptor
(1 time)
Biomedical Research
(1 time)
AML (1 time)
LAM (1 time)
TSC (1 time)
2018 TSC2-deficient tumors have evidence of T cell exhaustion and respond to anti-PD-1/anti-CTLA-4 immunotherapy.
36  programmed death 1 on T cells
(1 time)
Neoplasms
(1 time)
AEs (1 time)
CTLA-4 (1 time)
HRQoL (1 time)
2017 Health-related quality of life results from the phase III CheckMate 067 study.
37  programmed death 1 pathway
(1 time)
Neoplasms
(1 time)
PD-L1 (1 time)
2015 Anti-PD-1 therapy in melanoma.
38  Programmed death cell receptor 1
(1 time)
Allergy and Immunology
(1 time)
APC (1 time)
2011 Regulation of Trypanosoma cruzi-induced myocarditis by programmed death cell receptor 1.
39  programmed death-1 gene
(1 time)
Pediatrics
(1 time)
CAD (1 time)
KD (1 time)
OR (1 time)
2010 Programmed death-1 (PD-1) gene polymorphisms lodged in the genetic predispositions of Kawasaki Disease.